Noga Yerushalmi - Profile and Investment Details

Investor Profile

Noga Yerushalmi is a Venture Capital, Corporate Venture Capital, Investor, Private Equity Firm based in Israel with a diverse investment portfolio that includes companies such as FoRx Therapeutics, Micropsi Industries, Indi Molecular, Biolinq, Asceneuron, DNA Script, Peratech, Medisafe, Padlock Therapeutics, ARTSaVIT, Macrophage Pharma, Tipe, F-star Biotechnology, iOnctura, Synaffix BV, Akili Interactive Labs, Calypso Biotech, Translate Bio, SeeQC, FanAI, Ribometrix, Artios Pharma, Storm Therapeutics, Metalenz, SynSense, Forendo Pharma, Bird Rock Bio, Metabomed, NanoSyrinx, Xilio Therapeutics, Alcan Systems, Rewind Therapeutics, Canbex Therapeutics, curbFlow, Raze Therapeutics, Neurable, ApoGen Biotechnologies, Ambrx, aveni, Scipio Bioscience, Mighty Bear Games, Galecto, Progyny, Mosa Meat, Altoida, Anaphore, Inthera Bioscience, Wiliot, Gamelynx, IOmx Therapeutics, ObsEva, Prexton Therapeutics. Over time, Noga Yerushalmi has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Noga Yerushalmi is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Semiconductor, Black / African American Led, Infrastructure, Life Science, Food Processing, Electronics, Biotech, 3D Technology, Manufacturing, Healthcare, Biotechnology, Mobile Apps, Food and Beverage, Neuroscience, Internet, Medical, Sensors, Therapeutics, mHealth, Media and Entertainment, Quantum Computing, Black / African American Founded, Packaged Goods, Biopharma may find it worthwhile to explore potential connections with Noga Yerushalmi, as their portfolio suggests a familiarity and interest in this area.

Understanding Noga Yerushalmi’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.